Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maravai Lifesciences Holdings Inc Cl A (NQ: MRVI )

6.795 -0.045 (-0.66%)
Streaming Delayed Price Updated: 11:20 AM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Maravai Lifesciences Holdings Inc Cl A

< Previous 1 2 3 4 5 6 Next >
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Virpax Pharmaceuticals Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.18% to 35,204.03 while the NASDAQ fell 1.24% to 14,610.77. The S&P also fell, dropping 1.06% to 4,432.01. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market Near Highs, Treasury Yields Rally; Disney, Several IPOs Jump On Earnings
Stocks traded at highs this week despite some growth wobbles. Treasury yields rebounded. Disney and some IPOs jumped on earnings. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Arcturus Stock, A Covid Play, Flashes Vital Signs
A Relative Strength Rating upgrade for Alcobra shows improving technical performance. 
Via Investor's Business Daily
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2021 Earnings Call Transcript
MRVI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Biotech Maravai LifeSciences Sees RS Rating Rise To 89
Maravai Lifesciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 89. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Editas Medicine Stock Shows Improved Relative Strength Rating
A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech
Codex DNA Inc (NASDAQ: DNAY) has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc... 
Via Benzinga
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold
In a welcome move, biotech BridgeBio Pharma stock saw its Relative Strength Rating rise from 70 to 73 on Thursday. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Translate Bio Stock Sees Relative Strength Rating Jump To 88
A Relative Strength Rating upgrade for Translate Bio shows improving technical performance. 
Via Investor's Business Daily
Translate Bio Stock Flashes Improved Technical Strength Rating; Triple-Digit Sales Growth
Translate Bio shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Crispr Therapeutics Stock Sees Improved Relative Strength Rating
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74. 
Via Investor's Business Daily
Novan Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Novan shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Twist Bioscience Stock Hits 80-Plus Relative Strength Rating Benchmark
TwistBioscienceCorp shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82. 
Via Investor's Business Daily
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
BioNTech SE Stock Earns Membership In 95-Plus Composite Rating Club
The IBD SmartSelect Composite Rating for BioNTech SE stock rose from 94 to 97 Thursday. The Covid-19 vaccine stock also has 98 Relative Strength Rating. 
Via Investor's Business Daily
Exposures COVID-19
Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
BridgeBio Stock Flashes Healthy 83 RS Rating
Look for stocks with a Relative Strength Rating of 80 or higher. BridgeBio stock just hit that mark, with a jump from 79 to 83 Wednesday. 
Via Investor's Business Daily
Twist Bioscience Stock Scores Relative Strength Rating Upgrade
When adding stocks to your watch list, look for stocks with an 80 or higher RS Rating. Twist Bioscience just met that criteria with a new score of 84. 
Via Investor's Business Daily
Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Cel-Sci stock saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87, making the stock a potential watchlist candidate. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.